Drug profile · INN
abemaciclib
VERZENIO
abemaciclib (VERZENIO) is a cyclin-dependent kinase 6 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — abemaciclib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 20
- Programs
- 43
- Data quality
- 0.84
Quick answer
abemaciclib (VERZENIO) is a cyclin-dependent kinase 6 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cyclin-dependent kinase 6 inhibitor
Primary target: Cyclin-dependent kinase 4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
-
WO 2025233501
CONJUGUÉS COMPRENANT UN INHIBITEUR DE TOPOISOMÉRASE I
granted -
US 12427137
Method for reducing methane production in animal stomach
granted -
US 12389931
Oyster peptide with effect of improving sexual function and preparation method thereof
granted -
US 12331040
Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
granted -
US 12324798
Leonurine nanocomposite hydrogel and preparation methods and applications thereof
granted -
US 12297300
Hyaluronic acid-based zwitterionic polymer brush, preparation method thereof, and use thereof
granted -
US 12291530
GLP-1R agonist and therapeutic method thereof
granted -
US 12269808
Amino dithioperacid thioester compound, preparation method therefor, and use thereof
granted -
US 12234236
GLP-1R agonist and therapeutic method thereof
granted -
US 12226476
Helper epitope peptide and application thereof
granted -
US 12221414
Quaternary ammonium salt compound, preparation method therefor and use thereof
granted -
US 12144881
Cosmetic composition containing α-mangostin, method for preparation, and uses thereof
granted -
US 12110315
Fish-derived peptidoglycan recognition protein mutant and application thereof
granted -
US 12090227
Method to improve the encapsulation efficiency and physicochemical stability of ginsenosides Rg3 and CK nano-emulsion
granted -
US 12048317
Astaxanthin-containing condiment and a preparation method therefor
granted -
US 11976098
Cooked millet prolamin peptide for inhibiting alpha-amylase and alpha-glucosidase
granted -
US 11970523
Long-acting oxyntomodulin hybrid peptide, preparation method therefor, and application thereof
granted -
US 11970479
3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor
granted -
US 11963970
Preparation method of ginseng composition with high ginsenoside bioavailability
granted -
US 11957764
Protein-type nanoparticles, preparation methods, and application thereof
granted
Frequently asked questions
What is abemaciclib?
abemaciclib (VERZENIO) is a cyclin-dependent kinase 6 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for abemaciclib?
VERZENIO is a marketed brand name for abemaciclib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of abemaciclib?
abemaciclib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.